X4P-001

DRUG6 trials

Sponsors

X4 Pharmaceuticals, Abbisko Therapeutics Co, Ltd

Conditions

Clear Cell Renal Cell CarcinomaHealthyMelanomaTriple Negative Breast CancerWHIM Syndrome

Phase 1

Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma

CompletedNCT02667886

X4 PharmaceuticalsClear Cell Renal Cell Carcinoma

Start: 2016-04-27End: 2022-04-14Updated: 2024-10-03

A Study Comparing Once-Daily vs. Twice-Daily Dosing of X4P-001 in Healthy Volunteers

TerminatedNCT02680782

X4 PharmaceuticalsHealthy

Start: 2016-01-12End: 2016-02-28Updated: 2018-12-07

X4P-001 and Pembrolizumab in Patients With Advanced Melanoma

CompletedNCT02823405

X4 PharmaceuticalsMelanoma

Start: 2016-09-15End: 2018-03-15Updated: 2020-07-07

Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma

TerminatedNCT02923531

X4 PharmaceuticalsClear Cell Renal Cell Carcinoma

Start: 2016-12-07End: 2018-08-08Updated: 2022-12-29

A Study to Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBC

Abbisko Therapeutics Co, LtdTriple Negative Breast Cancer

Start: 2021-07-21End: 2023-05-21Target: 24Updated: 2021-11-02

Phase 2

A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

CompletedNCT03005327

X4 PharmaceuticalsWHIM Syndrome

Start: 2016-12-31End: 2022-06-16Updated: 2024-10-30

Related Papers

A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome

Blood2024-04-2135 citations

Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma

Cancer Research Communications2022-08-0920 citations

PB1938: 4WHIM: EVALUATING MAVORIXAFOR, AN ORAL CXCR4 ANTAGONIST, IN PATIENTS WITH WHIM SYNDROME VIA A GLOBAL PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL WITH OPEN-LABEL EXTENSION

HemaSphere2022-06-012 citations

Mavorixafor, an Oral CXCR4 Antagonist, for Treatment of Patients with WHIM Syndrome: Results from the Long-Term Extension of the Open-Label Phase 2 Study

Blood2021-11-054 citations

Global Phase 3, Randomized, Placebo-Controlled Trial with Open-Label Extension Evaluating the Oral CXCR4 Antagonist Mavorixafor in Patients with WHIM Syndrome (4WHIM): Trial Design and Enrollment

Blood2021-11-053 citations

A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy

Investigational New Drugs2021-01-2838 citations

Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome

Blood2020-09-0163 citations

Determination of Phase 3 Dose for X4P-001 in Patients with WHIM Syndrome

Blood2018-11-291 citations

A phase Ia/IIb trial of the CXCR4 inhibitor X4P-001 and nivolumab for advanced renal cell carcinoma (RCC) that is unresponsive to nivolumab monotherapy

Annals of Oncology2018-10-015 citations

Abstract 613: X4P-001, an orally bioavailable CXCR4 antagonist, enhances immune cell infiltration and activation in the tumor microenvironment of melanoma

Cancer Research2018-07-0110 citations

A phase 1/2 study evaluating the efficacy and safety of the oral CXCR4 inhibitor X4P-001 in combination with axitinib in patients with advanced renal cell carcinoma.

Journal of Clinical Oncology2018-05-208 citations